Metformin News and Research

RSS

Metformin is the active ingredient in a drug used to treat diabetes mellitus (a condition in which the body cannot control the level of sugar in the blood). It is also being studied in the treatment of cancer. It decreases the amount of glucose (a type of sugar) released into the bloodstream from the liver and increases the body’s use of the glucose. Metformin is a type of antidiabetic agent.

Common diabetes medication slows growth of precancerous esophageal cells, study shows

A common diabetes medication, metformin, slows the growth of precancerous cells in the oesophagus while some metabolic conditions accelerate it, suggests a new study.

16 Sep 2024

Ketogenic diet restores menstrual cycles and boosts fertility in women with PCOS

A ketogenic diet restored menstrual cycles in all women with PCOS in a study, with over half of those desiring pregnancy achieving it. The diet could be a promising approach to enhance fertility.

15 Sep 2024

Real-world evidence highlights safety profile of tirzepatide in managing type 2 diabetes

As more people with type 2 diabetes (T2D) are taking medications to help manage blood sugar levels and weight loss, concerns about whether these drugs are safe have emerged.

12 Sep 2024

Promising new approach to combat HIV

Researchers at Université de Montréal's affiliated hospital research center, the CRCHUM, say the discovery could help lessen and even eliminate viral loads in people undergoing antiretroviral therapy.

11 Sep 2024

Researchers uncover connection between two common diabetes drugs with implications for foot ulcer healing

Research shows elevated metformin in diabetic foot ulcer exudates when combined with insulin, highlighting potential for improved wound healing therapies.

9 Sep 2024

Combined use of insulin and metformin enhances diabetic foot ulcer healing, research shows

People with chronic diabetic foot ulcers could soon have a new way to treat their wounds for faster healing and fewer hospital stays.

4 Sep 2024

New approach to treat post-COVID symptoms

In a world still grappling with the aftermath of the COVID-19 pandemic, a team of international researchers has proposed a novel approach to treating the persistent symptoms that plague many survivors of viral infections. The study, published on 30 August 2024 in Brain Medicine (ISSN: 2997-2639, Genomic Press, New York), outlines a multimodal treatment strategy that could offer hope to millions suffering from post-acute infectious syndromes (PAIS), including the condition commonly known as Long COVID.

4 Sep 2024

SGLT-2 inhibitors show potential in preventing dementia in diabetes patients

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors used to treat type 2 diabetes might prevent dementia, providing greater benefits with longer treatment, suggests a large study from Korea published by The BMJ today.

28 Aug 2024

Clarification urgently needed for detected signal of semaglutide-linked suicidal ideation

Researchers investigate the potential link between the obesity drugs semaglutide and liraglutide and suicidal or self-injurious adverse drug reactions.

26 Aug 2024

Study finds potential for antidiabetic drugs to modify osteoarthritis risk

Whether antidiabetic medications could potentially be used as disease-modifying osteoarthritis drugs or DMOADs for the therapeutic management of osteoarthritis.

21 Aug 2024

Gut microbiota plays a crucial role in type 2 diabetes management

Research reveals the intricate role of gut microbiota in type 2 diabetes, highlighting personalized therapeutic strategies and the complexity of microbial interactions with antidiabetic drugs.

15 Aug 2024

Review of fasting-mimicking diets in cancer treatment

Researchers present the role of cyclic fasting and fasting-mimicking diets (FMD) in cancer therapy.

8 Aug 2024

A third of NHS shakes and soups diet participants achieve diabetes remission

Researchers assessed insulin-independent diabetes remission by total dietary replacement in England.

8 Aug 2024

How little Denmark got homegrown giant Novo Nordisk to lower ozempic prices

On May 13, Sen. Bernie Sanders (I-Vt.) published an open letter to Novo Nordisk on the front page of a leading Danish newspaper, urging the hometown company to live up to its altruistic standards by lowering U.S. prices for its blockbuster diabetes and weight loss drugs.

8 Aug 2024

Study reveals curcumin’s antidepressant effects in obese type 2 diabetes patients

A randomized clinical trial (RCT) to investigate the effectiveness of curcumin in lowering depression among obese individuals with diabetes mellitus type 2 (T2DM).

30 Jul 2024

Semaglutide may reduce smoking risks for diabetes patients

Semaglutide shows promise in reducing tobacco use disorder-related health encounters in patients with type 2 diabetes, but further clinical trials are needed to confirm its efficacy.

29 Jul 2024

Weill Cornell researchers define three Parkinson's subtypes with machine learning

Researchers at Weill Cornell Medicine have used machine learning to define three subtypes of Parkinson's disease based on the pace at which the disease progresses.

16 Jul 2024

Study reveals potential cognitive benefits of antidiabetic drugs

Investigators analyzing the potential cognitive effects of antidiabetic medications in records of more than 1.5 million patients with type 2 diabetes mellitus (T2DM) found risks of dementia and Alzheimer's disease (AD) were significantly lower in patients treated with metformin and sodium glucose co-transporter-2 inhibitors (SGLT-2i) compared to other antidiabetic drugs.

12 Jul 2024

Four years non-diabetic status after impaired glucose tolerance diagnosis cuts cardiovascular risks

Maintaining non-diabetic status for at least four years after impaired glucose tolerance diagnosis significantly lowers the risk of cardiovascular complications and mortality.

10 Jul 2024

Semaglutide linked to increased risk of severe eye condition NAION in new study

Research shows semaglutide users face a significantly higher risk of developing non-arteritic anterior ischemic optic neuropathy (NAION) compared to users of other medications for diabetes and obesity.

8 Jul 2024

Metformin News and Research

Further Reading

Common diabetes medication slows growth of precancerous esophageal cells, study shows

Ketogenic diet restores menstrual cycles and boosts fertility in women with PCOS

Real-world evidence highlights safety profile of tirzepatide in managing type 2 diabetes

Promising new approach to combat HIV

Researchers uncover connection between two common diabetes drugs with implications for foot ulcer healing

Combined use of insulin and metformin enhances diabetic foot ulcer healing, research shows

New approach to treat post-COVID symptoms

SGLT-2 inhibitors show potential in preventing dementia in diabetes patients

Clarification urgently needed for detected signal of semaglutide-linked suicidal ideation

Study finds potential for antidiabetic drugs to modify osteoarthritis risk

Gut microbiota plays a crucial role in type 2 diabetes management

Review of fasting-mimicking diets in cancer treatment

A third of NHS shakes and soups diet participants achieve diabetes remission

How little Denmark got homegrown giant Novo Nordisk to lower ozempic prices

Study reveals curcumin’s antidepressant effects in obese type 2 diabetes patients

Semaglutide may reduce smoking risks for diabetes patients

Weill Cornell researchers define three Parkinson's subtypes with machine learning

Study reveals potential cognitive benefits of antidiabetic drugs

Four years non-diabetic status after impaired glucose tolerance diagnosis cuts cardiovascular risks

Semaglutide linked to increased risk of severe eye condition NAION in new study

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News